1)Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720-1748,2022
2)Rossi D, Terzi-di-Bergamo L, De Paoli L, et al:Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 126:1921-1924,2015
3)Kater AP, Wu JQ, Kipps T, et al:Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol 38:4042-4054,2020
4)International CLL-IPI working group:An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17:779-790,2016
5)Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140:1229-1253,2022
6)Laurent C, Adélaïde J, Guille A, et al:High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B. Am J Surg Pathol 45:1324-1336,2021